Cytocore (OTCMKTS:MDIT) and Alphatec (NASDAQ:ATEC) are both small-cap medical companies, but which is the better investment? We will contrast the two companies based on the strength of their dividends, risk, analyst recommendations, valuation, institutional ownership, profitability and earnings.
Volatility and Risk
Cytocore has a beta of 3.66, meaning that its stock price is 266% more volatile than the S&P 500. Comparatively, Alphatec has a beta of 1.52, meaning that its stock price is 52% more volatile than the S&P 500.
This table compares Cytocore and Alphatec’s net margins, return on equity and return on assets.
|Net Margins||Return on Equity||Return on Assets|
This is a breakdown of recent ratings for Cytocore and Alphatec, as provided by MarketBeat.
|Sell Ratings||Hold Ratings||Buy Ratings||Strong Buy Ratings||Rating Score|
Alphatec has a consensus price target of $8.00, suggesting a potential upside of 13.48%. Given Alphatec’s higher probable upside, analysts clearly believe Alphatec is more favorable than Cytocore.
Institutional & Insider Ownership
38.1% of Alphatec shares are owned by institutional investors. 85.4% of Cytocore shares are owned by insiders. Comparatively, 34.3% of Alphatec shares are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.
Earnings & Valuation
This table compares Cytocore and Alphatec’s top-line revenue, earnings per share and valuation.
|Gross Revenue||Price/Sales Ratio||Net Income||Earnings Per Share||Price/Earnings Ratio|
|Cytocore||$6.81 million||0.25||-$6.81 million||N/A||N/A|
|Alphatec||$91.69 million||4.72||-$28.98 million||($0.58)||-12.16|
Cytocore has higher earnings, but lower revenue than Alphatec.
Cytocore beats Alphatec on 6 of the 11 factors compared between the two stocks.
MEDITE Cancer Diagnostics, Inc. operates as a medical technology company. It develops, manufactures, and markets molecular biomarkers, medical devices, and consumables for the detection, risk assessment, and diagnosis of cancerous and precancerous conditions and related diseases. The company offers USE 33, an ultrasonic decalcification instrument that automatically runs the process under controlled temperatures; TPC 15 Duo and Trio, a tissue processing instrument; TES 99 and TES Valida cooling units; and M530, A550, M380 microtomes for tissue sectioning. It also provides M630, a freezing microtome; TST44, a robotic multi-staining system; COT 20, a linear staining system; and RCM 9000, ACS 720, and TWISTER robotic coverslippers. In addition, the company develops SoftKit device for the self-collection of a sample that can be evaluated to provide an assessment of the health of the entire female genital tract. It sells its products through direct sales and distributors in the United States, China, Europe, and North Africa. The company serves histology and cytology laboratories associated with hospitals or research institutions, and independent laboratories. MEDITE Cancer Diagnostics, Inc. is headquartered in Orlando, Florida.
Alphatec Holdings, Inc., a medical technology company, focuses on the design, development, and promotion of products for the surgical treatment of spine disorders. Its product portfolio and pipeline address the cervical, thoracolumbar, and intervertebral regions of the spine; and cover various spinal disorders and surgical procedures. The company offers MIS products consisting of Battalion Lateral Spacer System and Squadron Lateral Retractor, Illico Minimally Invasive Surgery System, and BridgePoint Spinous Process Fixation System; and fixation products, such as Arsenal Screw System and Zodiac Spinal Fixation Systems. It also provides cervical and cervico-thoracic products, including Trestle Luxe Anterior Cervical Plate System, and Solanas Posterior Cervico/Thoracic Fixation System and Avalon Occipital Plate; and interbody Systems, such as Battalion Universal Spacer System, Novel PEEK and Titanium Spinal Spacers, and Alphatec Solus Locking ALIF Spinal Spacer. In addition, the company offers biologics consisting of AlphaGraft Structural Allograft Spacers, AlphaGraft ProFuse Demineralized Bone Scaffold, Amnioshield Amniotic Tissue Barrier, Alphagraft Demineralized Bone Matrix, and Neocore Osteoconductive Matrix. It sells its products through a network of independent distributors and direct sales representatives in the United States. Alphatec Holdings, Inc. was founded in 1990 and is headquartered in Carlsbad, California.
Receive News & Ratings for Cytocore Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cytocore and related companies with MarketBeat.com's FREE daily email newsletter.